Abstract
Characterization of immunogenic tumor-associated antigens (TAA) is mandatory for the design of cancer vaccines. Cancer antigens eliciting an immune response in the tumor-bearing host are targets for specific immunotherapy. In recent years, many TAA have been identified by methods using cytotoxic T-lymphocytes or by serological screening of recombinant expression cloning. TAA can be classified into three major categories:
-
1.
Overexpressed genes are known to elicit immune responses by overriding thresholds critical for the maintenance of tolerance [1]. These antigens are not strictly tumor-specific, but they are overexpressed in different tumor tissues.
-
2.
Antigens encoded by mutated genes induce immune responses by changing the expression and/or conformation of proteins [2].
-
3.
Cancer/testis (CT) antigens are a family of tumor genes expressed exclusively in cancer cells and in testis tissue [3].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Viola A, Lanzavecchia A (1996) T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104–106
Coulie PG, Lehmann F, Lethe B, Hermann J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci 92: 7976–7980
Chen YT, Scanlan MJ, Sahin U, Türeci Ö, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci 94: 1914–1918
Ikeda H, Lethe B, Lehmann F, Van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6: 199–208
Neumann E, Engelsberg A, Decker J, Störkel S, Jäger E, Huber C, Seliger B (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies. Cancer Res 58: 4090–4095
Van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG (1998) PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 102: 1376–1379
Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Maurer U, Bergmann L, Schmitt M (2000) Simultaneous expression of different immunogenic antigens in acute myeloid leukemia (AML). Exp J Heamatol 28: 1413–1422
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156
Bièche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud M (1999) Quantitation of MYC Gene Expression in Sporadic Breast Tumors with a Real-Time Reverse Transcription-PCR Assay. Cancer Res 59: 2759–2765
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1998) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712
Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268–276
Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, Veelen van PA, Kloostermann-Joosten AM, Vissers DCJ, Bosch GJA, Kester MGD, Sijts A, Drijthout JW, Ossendorp F, Offringa R, Melief CJM (2001) Efficient identification of novel HLA-A 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 193: 73–88
Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D (1997) High levels of Wilms’ tumor gene (wtl) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90 (3): 1217–25
Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L (1997) Wilms tumor gene (wtl) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 90: 4230–4232
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Greiner, J., Ringhoffer, M., Szmaragowska, A., Hübsch, S., Döhner, H., Schmitt, M. (2002). Quantitative Measurement of the mRNA Expression of the Tumor-Associated Antigen PRAME by Real-Time RT-PCR Using LightCycler and SYBR Green I Technology. In: Dietmaier, W., Wittwer, C., Sivasubramanian, N. (eds) Rapid Cycle Real-Time PCR — Methods and Applications. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59397-0_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-59397-0_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63965-4
Online ISBN: 978-3-642-59397-0
eBook Packages: Springer Book Archive